Trim 30–35% of BMY ahead of Q3 earnings; retain 65–70% core for dividend carry and re-engagement optionality
Underweight wins because three binding reflections converge on calibrated trim: (1) The 9/28 dispositive lesson mandates trim 25–40% on broken momentum — confirmed by current MACD histogram widening from -0.21 to -0.26, RSI 37.95, only $0.83 buffer to 200 SMA, distribution volume 19.2M+. (2) The 9/17 + 9/10 floor-integrity reflections cap magnitude at lower end of band — 0.18 beta, 2.5× FCF coverage, $12.8B TTM FCF, $5.9B deleveraging, 200 SMA still holding, 17 consecutive years of dividend growth. (3) The 10/5 lesson directs that at RSI approaching but not at extreme oversold (<35), trim magnitude defaults toward the lower end of the cited band (30–35%, not 40%+).
| Position | Action |
|---|---|
| Core position | Trim 30–35% of BMY holdings; retain 65–70% core |
| Re-entry | Cap at 50% of normal sizing pending explicit 10 EMA reclaim with MACD positive + RSI >50 |
| Stop-loss trigger | Auto-revert to Sell on close <$58.24 with volume >15M |
BMY at $59.70 represents a rare combination of technical support at the rising 200-day trendline, a 3:1 risk-reward ratio, and historically cheap valuation (9x forward P/E with a 4.23% dividend) in a macro environment poised to favor defensive income payers, with Q3 earnings as a near-term catalyst for multiple expansion.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 37.95 | neutral |
| MACD (12,26,9) | -1.06 | bearish |
| MACD Signal | -0.79 | bearish |
| MACD Histogram | -0.26 | bearish |
| 10 EMA | 60.74 | bearish |
| 50 SMA | 63.69 | bearish |
| 200 SMA | 58.24 | bullish |
| Bollinger Lower | 59.07 | neutral |
| Bollinger Mid | 61.73 | neutral |
| Bollinger Upper | 64.40 | neutral |
| ATR (14) | 1.42 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: 10 EMA reclaim with MACD positive + RSI >50
Then: Re-enter at 50% normal sizing
Eliquis LoE risk is already priced in at the ~13% peak-to-current drawdown
↩ rebuts: “Bear claim that Eliquis exclusivity loss will 'destroy' the company is priced in at current levels”
EV: +6.7% to 50 SMA at $63.69; +13.8% to August high at $67.94; +20-30% on multiple expansion (9x to 11-12x forward P/E) · concedes: Capitulation-style action at lower Bollinger band historically precedes relief bounce, not always fresh breakdown — a 2.5% breakdown below $58 is possible; Eliquis LoE is a real risk that has not fully played out, just partially priced in; D/E of 2.55x is high relative to non-pharma sectors; Negative tangible book value is a structural feature of major acquirers (Celgene, Karuna, RayzeBio, Mirati), not a deal-breaker but a valid concern
BMY is in a confirmed technical downtrend with bearish moving average stack, faces $12-13B Eliquis franchise erosion of $1.5-2.5B annually starting late 2026/2027, has pipeline estimates that are too optimistic, carries $34.9B net debt at 1.8x EBITDA, and has a Q3 earnings setup skewed to the downside — making the risk-reward approximately 1:1, not 3:1.
EV: -$3.70 to -$4.70 (6-8% downside from $59.70 to $55-56 zone) · concedes: 4.23% dividend yield is historically attractive relative to BMY's own history; Deleveraging trajectory is directionally correct (from $39.3B net debt in 2024 to $34.9B in 2025); Long-term fundamental value case is not unreasonable if pipeline executes; Patient capital waiting for actual reversal rather than hope is a valid strategy
→ vs conservative: The 200 SMA at 58.24 is a tripwire, not a backstop—conservative 'wait for breakdown below 58' means chasing into 55-56 zone after missing the move; 'add if price reclaims 10 EMA at 60.74' is buying resistance not support; the year-long 200 SMA uptrend from 47.70 is now being tested with momentum already broken, and such breakdowns from rising 200 SMAs after extended runs often knife through with volume
→ vs neutral: The 'defensive rotation thesis' requires yield decline that isn't happening—Polymarket has 96% no Fed cuts in 2026 priced; rising yields and steepening curve discount pharma's long-duration cash flows harder; 'constructive lean over 3-6 months' ignores the binary earnings catalyst with negative pre-earnings drift where downside of 5-8% on miss vastly outweighs upside on beat, especially with Eliquis LoE overhang
| neutral |
Support: 59.07 · 58.24 · 58.81 | Resistance: 60.74 · 61.73 · 63.27 · 63.69 · 64.4 · 67.94
BMY exhibits a bearish stacked structure (price < 10 EMA < 50 SMA) with all short/medium-term trend indicators aligned downward. The 200 SMA at 58.24 remains the linchpin support, with the October 5th gap-down to 58.81 confirming recent weakness partly mechanically tied to the $0.63 ex-dividend. MACD bearish crossover occurred ~2026-09-21 and momentum has not yet bottomed. Price is hugging the lower Bollinger band (59.07), which historically precedes either capitulation or mean-reversion bounces. ATR compression to 1.42 (down ~20% from August) signals declining volatility. Bearish momentum divergence was confirmed in August-September (price made higher high at 67.39 on 09-03 while RSI dropped from 69.0 to 64.1). Rating: HOLD.
Market Cap
$121.95 B
52-Week High
$68.64
52-Week Low
$42.52
Current Price
~$59.70
50-Day Avg
$64.38
200-Day Avg
$59.45
Beta
0.18
PE Ratio (TTM)
13.15
Forward PE
9.06
PEG Ratio
16.59
Price / Book
5.46
EPS (TTM)
$4.54
Forward EPS
$6.59
Dividend Yield
4.23%
Revenue FY2025
$48.20 B
Revenue FY2024
$48.30 B
Net Income FY2025
$7.05 B
Net Income FY2024
($8.95 B)
Diluted EPS FY2025
$3.46
Diluted EPS FY2024
($4.41)
Gross Margin TTM
71.7%
Operating Margin TTM
34.4%
Net Margin TTM
18.9%
ROE
46.6%
ROA
10.7%
EBITDA TTM
$18.93 B
Free Cash Flow FY2025
$12.85 B
Operating Cash Flow FY2025
$14.16 B
CapEx FY2025
$1.31 B
Total Assets FY2025
$90.04 B
Total Debt FY2025
$47.14 B
Net Debt FY2025
$34.90 B
Cash & Equivalents FY2025
$10.67 B
Stockholders Equity FY2025
$18.47 B
Current Ratio FY2025
1.53
Debt / Equity FY2025
2.55x
Dividends Paid FY2025
$5.05 B
Share Repurchases FY2025
$0 (paused)
Goodwill FY2025
$21.75 B
Other Intangibles FY2025
$19.35 B
Tangible Book Value
$-22.6 B
Normalized EBITDA FY2025
$19.95 B
Strengths
Concerns
Bristol-Myers Squibb is a mature, cash-generative pharma giant navigating a critical transition from legacy blockbuster Eliquis (facing generic erosion 2026-2028) to new growth drivers anchored by Cobenfy (schizophrenia) and radiopharmaceuticals (RayzeBio). FY2025 results show operational recovery with $7.05B net income and $12.85B FCF despite revenue stagnation at ~$48B. The balance sheet remains stretched with $34.9B net debt and negative tangible book value, but aggressive deleveraging and the 4.23% dividend yield provide income support. Forward valuation appears attractive at PE 9.06 given the analyst consensus of 45% EPS growth to $6.59, though this hinges entirely on successful Cobenfy ramp and pipeline execution.
Macro: The dominant macro variable is a hawkish rate path with 96% probability of no Fed cuts in 2026 (down marginally 1.2pp week-over-week), pushing the 10-year Treasury yield to its highest level since 2002. The September jobs report came in below consensus, supporting a "soft-landing lite" scenario with just 6% recession probability priced by year-end 2026. Geopolitical inflation (Iran war) is re-accelerating, arguing against any near-term Fed pivot. Equities hit record highs led by Nvidia/AMD tech while Bitcoin broke below $83K (risk-off tell), creating an unusual divergence between bond and equity markets that suggests positioning-driven equity strength rather than broad risk-on conviction. Consumer discretionary is the worst-hit sub-sector from higher rates, while pharma sits on the opposite side of that rotation.